Vectura Group Plc (VEC):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Vectura Group Plc (VEC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10105
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:71
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Vectura Group Plc (Vectura) is a formulation and device business for inhaled airways products providing an integrated inhaled drug delivery platform. It develops inhalation products, to help patients suffering from airways diseases such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, pulmonary fibrosis and other diseases. The company develops products based on a wide range of proprietary lung delivery technologies, including device and formulation capabilities. Vectura has a varied portfolio of drugs in clinical development, comprising several novel and generic programs that are partnered with several global biotechnology and pharmaceutical companies. Vectura is headquartered in Chippenham, Wiltshire, the UK.

Vectura Group Plc (VEC) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Vectura Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Vectura Group Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Vectura Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Vectura Group Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Vectura Group Plc, Medical Devices Deals, 2012 to YTD 2018 10
Vectura Group Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Vectura Group Plc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
SkyePharma Acquires Novel Inhaled Therapy Platform from Pulmagen Therapeutics 13
Partnerships 14
Ablynx Exercises Option for Licensing Agreement with Vectura 14
Vectura Enters into Agreement with Dynavax Technologies 15
Vectura Enters into Development and License Agreement with Janssen Biotech 16
Activaero Enters Into Research Agreement With Stanford University 17
Vectura Enters Into Co-Development Agreement With UCB For Biologic Immunomodulatory Product 18
Activaero Enters Into Research Agreement With Chiesi Farmaceutici 19
Vectura, Tianjin KingYork Group And Zendex Bio Strategy Form Respiratory Joint Venture In China 20
Activaero Enters Into Co-Development Agreement With TransMIT 21
Tianjin KingYork Forms Joint Venture With Innovata For Asthma And COPD Drugs 22
Merger 23
SkyePharma Merges with Vectura 23
Licensing Agreements 25
Vectura Group Enters into Licensing Agreement with Pulmatrix 25
Sandoz Enters into Licensing Agreement with Vectura 26
Mundipharma Enters into Licensing Agreement with Vectura for VR2076 27
Skyepharma Enters into Licensing Agreement with Lucideon 28
Mundipharma Enters into Licensing Agreement with SkyePharma and Sanofi for Flutiform 29
SkyePharma Enters into Option Agreement with Mundipharma 30
Vectura Enters into Licensing Agreement with US-Based Pharma Company for VR506 31
Hikma Pharma Enters into Licensing Agreement with Vectura Group for VR730 32
Equity Offering 33
SkyePharma Completes Private Placement Of Shares For US$187 Million 33
SkyePharma Completes Rights Offering Of Shares 34
Vectura Group Completes Private Placement Of Shares For US$46 Million 35
Ventaleon Spin Out from Activaero 36
Acquisition 37
GlaxoSmithKline May Acquire Vectura for USD1.62 Billion 37
Vectura Acquires Activaero, Medical Device Company, For US$181 Million 38
Vectura Group Plc – Key Competitors 40
Vectura Group Plc – Key Employees 41
Vectura Group Plc – Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Recent Developments 43
Financial Announcements 43
Sep 11, 2018: Vectura Group: Interim Results 43
Mar 21, 2018: Vectura Group: 2017 Preliminary Results 52
Mar 21, 2018: Vectura Group: 2017 Preliminary Results – Performance in-line with expectations, with strong in-market growth from key inhaled products 53
Sep 06, 2017: Vectura Group: 2017 Interim Results 55
Mar 21, 2017: Vectura Group: Preliminary Results for the nine-month period ended 31 December 2016 57
Mar 21, 2017: Vectura Group Announces Preliminary Results for the nine-month period ended 31 December 2016 59
Corporate Communications 60
Oct 22, 2018: Vectura group has announced the board change 60
Jul 16, 2018: Vectura Appoints Paul Fry as Chief Financial Officer and Executive Director 61
Jun 01, 2018: Vectura Group Appoints Anne Whitaker As Non-Executive Director 62
Apr 20, 2018: Vectura Announces Senior Management Change 63
Apr 20, 2018: Vectura Group: Directorate Change – Chief Financial Officer 64
Mar 06, 2017: Vectura Group: Board Change 65
Clinical Trials 66
May 22, 2017: Positive outcomes of the Phase I clinical study on VR942 presented at the American Thoracic Society 113th annual conference 66
Jan 24, 2017: FDA approves IND to support Vectura’s wholly-owned programme VR647 in paediatric asthma 67
Other Significant Developments 68
Oct 24, 2017: Vectura Group: Ultibro Breezhaler continues to deliver strong underlying growth in Q3 68
Feb 16, 2017: Vectura achieves £9 million royalty cap from GSK Ellipta® products 69
Jan 11, 2017: Vectura Group: Pre-close update 70
Appendix 71
Methodology 71
About GlobalData 71
Contact Us 71
Disclaimer 71

List of Tables
Vectura Group Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Vectura Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Vectura Group Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Vectura Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Vectura Group Plc, Deals By Therapy Area, 2012 to YTD 2018 9
Vectura Group Plc, Medical Devices Deals, 2012 to YTD 2018 10
Vectura Group Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
SkyePharma Acquires Novel Inhaled Therapy Platform from Pulmagen Therapeutics 13
Ablynx Exercises Option for Licensing Agreement with Vectura 14
Vectura Enters into Agreement with Dynavax Technologies 15
Vectura Enters into Development and License Agreement with Janssen Biotech 16
Activaero Enters Into Research Agreement With Stanford University 17
Vectura Enters Into Co-Development Agreement With UCB For Biologic Immunomodulatory Product 18
Activaero Enters Into Research Agreement With Chiesi Farmaceutici 19
Vectura, Tianjin KingYork Group And Zendex Bio Strategy Form Respiratory Joint Venture In China 20
Activaero Enters Into Co-Development Agreement With TransMIT 21
Tianjin KingYork Forms Joint Venture With Innovata For Asthma And COPD Drugs 22
SkyePharma Merges with Vectura 23
Vectura Group Enters into Licensing Agreement with Pulmatrix 25
Sandoz Enters into Licensing Agreement with Vectura 26
Mundipharma Enters into Licensing Agreement with Vectura for VR2076 27
Skyepharma Enters into Licensing Agreement with Lucideon 28
Mundipharma Enters into Licensing Agreement with SkyePharma and Sanofi for Flutiform 29
SkyePharma Enters into Option Agreement with Mundipharma 30
Vectura Enters into Licensing Agreement with US-Based Pharma Company for VR506 31
Hikma Pharma Enters into Licensing Agreement with Vectura Group for VR730 32
SkyePharma Completes Private Placement Of Shares For US$187 Million 33
SkyePharma Completes Rights Offering Of Shares 34
Vectura Group Completes Private Placement Of Shares For US$46 Million 35
Ventaleon Spin Out from Activaero 36
GlaxoSmithKline May Acquire Vectura for USD1.62 Billion 37
Vectura Acquires Activaero, Medical Device Company, For US$181 Million 38
Vectura Group Plc, Key Competitors 40
Vectura Group Plc, Key Employees 41
Vectura Group Plc, Subsidiaries 42

List of Figures
Vectura Group Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Vectura Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Vectura Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Vectura Group Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Vectura Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Vectura Group Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Vectura Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Vectura Group Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Vectura Group Plc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Vectura Group Plc (VEC):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Adamas Pharmaceuticals Inc (ADMS):製薬・医療:M&Aディール及び事業提携情報
    Summary Adamas Pharmaceuticals Inc (Adamas Pharmaceuticals) is a pharmaceutical company that develops and commercializes therapeutics for chronic disorders of the central nervous system. The company's Gocovri, formerly ADS-5102, is an amantadine extended-release (XR) formulation for the treatment fo …
  • Proteus Digital Health Inc:医療機器:M&Aディール及び事業提携情報
    Summary Proteus Digital Health Inc (Proteus) is a digital medicine company that develops and sells medicines for chronic diseases through in-house research and through partnership with the pharmaceutical, medical device and biotechnology companies. Its flagship product, Proteus Discover digital medi …
  • Enerchem International Inc:企業の戦略的SWOT分析
    Enerchem International Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • China Telecom Corporation Limited:戦略・SWOT・企業財務分析
    China Telecom Corporation Limited - Strategy, SWOT and Corporate Finance Report Summary China Telecom Corporation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Aegis Therapeutics LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Aegis Therapeutics LLC (Aegis Therapeutics) is a drug-delivery and drug-formulation technologies company that commercializes drug delivery and protein stabilization technologies through product specific licenses to pharmaceutical and biopharmaceutical companies. The company offers Intravail, …
  • Quadra – Power Generation:企業の発電所・SWOT分析2018
    Quadra - Power Generation - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key emp …
  • Laboratorios Farmaceuticos Rovi SA (ROVI):企業の財務・戦略的SWOT分析
    Summary Laboratorios Farmaceuticos Rovi SA (Rovi) is a pharmaceutical company engaged in the research, development, manufacturing, and marketing of prescription and hospital products. The company's product portfolio includes licensed prescription pharmaceuticals in the therapeutic areas of cardiovas …
  • Daimler AG (DAI)-エネルギー分野:企業M&A・提携分析
    Summary Daimler AG (Daimler) is an automobile company that undertakes the manufacture, distribution and sales of premium passenger cars, commercial vehicles and related spare part and accessories. The company also provides services such as financing, leasing, fleet management, insurance, financial i …
  • Software AG (SOW):企業の財務・戦略的SWOT分析
    Summary Software AG (SAG) is a technology company that provides software management solutions. The company offers digital business platform with integration, process management, adaptive application development, real-time analytics and enterprise architecture management. Its products include Adabas …
  • Viking Therapeutics Inc (VKTX):企業の財務・戦略的SWOT分析
    Summary Viking Therapeutics Inc (Viking Therapeutics) is a clinical-stage biopharmaceutical company that develops novel therapies for patients suffering from metabolic and endocrine disorders. Its lead clinical program product candidate include VK5211, an orally available, non-steroidal selective an …
  • CVS Health Corporation:企業のM&A・事業提携・投資動向
    CVS Health Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's CVS Health Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …
  • Antares Pharma Inc (ATRS):企業の財務・戦略的SWOT分析
    Antares Pharma Inc (ATRS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Ormat Technologies Inc (ORA):企業の財務・戦略的SWOT分析
    Ormat Technologies Inc (ORA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Kingdom Hotel Investments:企業の戦略・SWOT・財務分析
    Kingdom Hotel Investments - Strategy, SWOT and Corporate Finance Report Summary Kingdom Hotel Investments - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Kering SA:企業のM&A・事業提携・投資動向
    Kering SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Kering SA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capita …
  • Cleveland BioLabs, Inc.:企業のM&A・事業提携・投資動向
    Cleveland BioLabs, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Cleveland BioLabs, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisition …
  • OZ Minerals Ltd:企業の戦略・SWOT・財務情報
    OZ Minerals Ltd - Strategy, SWOT and Corporate Finance Report Summary OZ Minerals Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Tredegar Corp (TG):企業の財務・戦略的SWOT分析
    Tredegar Corp (TG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Provimi Holding BV:企業の戦略・SWOT・財務分析
    Provimi Holding BV - Strategy, SWOT and Corporate Finance Report Summary Provimi Holding BV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Intercept Pharmaceuticals Inc (ICPT):製薬・医療:M&Aディール及び事業提携情報
    Summary Intercept Pharmaceuticals Inc (Intercept) is a biopharmaceutical company that researches, develops and commercializes treatments for non-viral, progressive liver diseases. It develops products using its proprietary bile acid chemistry. The company’s lead product candidate, obeticholic acid ( …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆